When implementing clinical pharmacokinetics consultation services for ambulatory patients, one should strongly consider developing an outpatient pharmacokinetics laboratory. Published literature clearly documents the benefits of clinical pharmacokinetics services. In addition, there are educational, financial, and research advantages to creating an outpatient pharmacokinetics laboratory. One should demonstrate the need for the service; determine the scope of services; design patient and specimen work flow; decide what personnel, space, and equipment are needed; and justify costs and revenue. Recent federal legislation, such as the Clinical Laboratory Improvements Amendments and the Occupational Exposure to Hazardous Chemical in Laboratories Act (1988), will have a significant positive impact on an outpatient pharmacokinetics laboratory.
Get full access to this article
View all access options for this article.
References
1.
Bendayan R., Robinson JD, Stewart RB: Pharmaceutical services in family practice medical residency training programs . Am J Hosp Pharm40:274-277, 1990
2.
Robinson JD: Pharmacokinetic services for ambulatory patients. Am J Hosp Pharm38:1713-1716, 1981
3.
Gums JG, Robinson JD: Pharmacokinetic monitoring in the community health-care setting. Drug Intell Clin Pharm21:422-426, 1987
4.
Robinson JD, Lopez LM, Stewart WL: How to establish a pharmacokinetics consulting service for ambulatory patients . Am J Hosp Pharm41:2048-2056, 1984
5.
Burkle WS: Development and implementation of clinical pharmacokinetic services . Am J Hosp Pharm47:391-394,1990
6.
Murphy JE, Ward ES, Job ML: Implementing and maintaining a private pharmacokinetics practice. Am J Hosp Pharm47:591-597,1990
7.
Taylor WJ, Robinson JD, Slaughter RL: Establishing a pharmacy-based therapeutic drug monitoring service . Drug Intell Clin Pharm19:818-824, 1985
8.
Ambrose PJ, Smith WE, Palarea ER: A decade of experience with a clinical pharmacokinetics service. Am J Hosp Pharm45:1879-1886, 1988
9.
Rietscha WJ, Heissler JF, Paulson MF, et al: Collaborative clinical pharmacokinetics service in a community hospital. Am J Hosp Pharm41:473-477, 1984
10.
Pitterle ME, Sorkness CA, Wiederholt JB: Use of serum drug concentrations in outpatient clinics. Am J Hosp Pharm42:1547-1552,1985
11.
Kildoo CW, Bolger PB, Ambrose PJ, et al: Use of serum drug concentrations in a private outpatient clinic . Am J Hosp Pharm44:1410-1411, 1987
12.
Ives TJ, Parry JL, Gwyther RE: Serum drug level utilization review in a family medicine residency program . J Fam Pract19:507-512, 1984
13.
Ried LD, McKenna DA, Horn JR: Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. Am J Hosp Pharm46:945-951, 1989
14.
American Society of Hospital Pharmacy: ASHP statement on the role of the pharmacist in clinical pharmacokinetic services . Am J Hosp Pharm39:1369,1982
15.
Ellison MJ, Horner RD, Willis SE, et al: Influence of pentoxifylline on steady-state theophylline serum concentrations from sustained-release formulations. Pharmacother10:383-386, 1990
16.
Robinson JD, Taylor WJ: Interpretation of serum drug concentrations, in Taylor WJ, Caviness MHD (eds): A Textbook for the Clinical Application of Therapeutic Drug Monitoring. Irving, TX, Abbott Laboratories, Diagnostic Division , 1986, pp 31-45
17.
National Committee for Clinical Laboratory Standards: Development of requisition forms for therapeutic drug monitoring and/or overdose toxicity; Approved guideline. NCCLS Document TIDM1-A. Villanova, PA, NCCLS, 1991
18.
Waller DJ, Smith SR: Assuring the quality of a clinical pharmacokinetics service. Am J Hosp Pharm43:2184-2188,1986
19.
Pearce GA, Day RO: Compliance with criteria necessary for effective drug concentration monitoring . Ther Drug Monit12:250-257, 1990
20.
Robinson JD , Dallman JJ: Pharmacokinetic education for family medicine physicians. Fam Med15:87-88, 1983
21.
D'Angio RG, Stevenson JG, Lively BT, et al: Therapeutic drug monitoring: Improved performance through educational intervention. Ther Drug Monit12:173-181, 1990
22.
Pippenger CE : Therapeutic drug monitoring in the 1990s. Clin Chem35:1348-1351, 1989
23.
Kauffman RE : Drug assays in the office. J Pediatr116:268-270, 1990
24.
Nierenberg DW: Measuring drug levels in the office: Rationale, possible advantages, and potential problems. Med Clin North Am71:653-664,1987
25.
Oles KS: Therapeutic drug monitoring analysis systems for the physician office laboratory: A review of the literature. DICP, Ann Pharmacother24:1070-1077, 1990 26. Blecka LJ, Jackson GJ: Immunoassays in therapeutic drug monitoring. Clin Lab Med7:357-370,1987
26.
Zuk RF, Ginsberg VK, Houts T., et al: Enzyme immunochromatography—A quantitative immunoassay requiring no instrumentation. Clin Chem31:1144-1150, 1985
27.
Oeltgen PR, Shank WA, Blouin RA, et al: Clinical evaluation of the Abbott TDx fluorescence polarization immunoassay analyzer. Ther Drug Monit6:360-367, 1984
28.
Centers for Disease Control: Recommendations for prevention of HIV transmission in health-care settings . MMWR36:3S-18S, 1987 (suppl 2S)
29.
Centers for Disease Control: Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings . MMWR37:377-388, 1988
30.
Clinical Laboratory Improvement Amendments of 1988: HR 5471, October 6, 1988
31.
Medicare, Medicaid and CLIA programs: Regulations implementing the clinical laboratory improvement amendments of 1988 (CLIA '88); proposed rule. Fed Reg55:20896-20959, 1990
32.
Goldsmith MF : Federal proficiency testing requirements set to start for physician office laboratories. JAMA262:2355-2356, 1989
33.
Fischer PM: Federally regulated office laboratories. Am Fam Physician40:95-96, 1989
34.
Garbo MJ, Comeau NA, Swanson KA: OSHA hazard communication standard: Helping prevent chemical hazards . AAOHN J36:366-371, 1988
35.
Solomon CJ: Implementing the hazard communication standard. AAOHN J36:372-374, 1988
36.
Kilby JA: New OSHA standard goes into effect regarding safety in laboratories . Occup Health Saf59:82-83, May, 1990
37.
Rekus JF: Implementing chemical-hygiene plan focus of OSHA's new lab standard . Occup Health Saf60:52-59, February, 1991
38.
Baer DM, Skeels MR, Belsey R.: Regulation of physicians' office laboratories. Med Lab Observer20:26-32, 1988
39.
National Committee for Clinical Laboratory Standards: Physician's office laboratory guidelines and procedure manual: Tentative guideline. NCCLS Document POL1 / 2-T. Villanova, PA, NCCLS, 1991
40.
Commission on Office Laboratory Assessment : Special issue: CLIA'88 proposed rule released. COLA Update1:1-4,1990
41.
Lawson LA, Bluoin RA, Parker PF: Quality assurance program for a clinical pharmacokinetic service. Am J Hosp Pharm39:607-609,1982
42.
Burkle WS, Matzke GR, Lucarotti RL: Development of competency standards for quality assurance in clinical pharmacokinetics . Hosp Pharm15:494-496, 1980
